Lilly cuts insulin prices by 70%, caps patient insulin out-of-pocket at $35

UTAH — Eli Lilly and Company announced on March 1 that it will reduce the price of its most commonly prescribed insulins by 70%, and cap patient out-of-pocket costs at $35 a month.

According to a press release from the company, Lilly is taking these actions to make it easier to access insulin, and help Americans navigating a complex healthcare system that may keep them from getting affordable insulin.

“While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change,” David A. Ricks, Lilly’s chair and CEO, said in a press release. “The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes… we are driving for change in repricing older insulins, but we know that 7 out of 10 Americans don’t use Lilly insulin. We are calling on policymakers, employers and others to join us in making insulin more affordable.”

Lilly is reducing the price of the following insulins:

  • Cutting the list price of its non-branded insulin, Insulin Lispro Injection 100 units/mL, to $25 a vial, effective May 1, 2023.
  • Cutting the list price of Humalog® (insulin lispro injection) 100 units/mL1, Lilly’s most commonly prescribed insulin, and Humulin® (insulin human) injection 100 units/mL2 by 70%, effective in Q4 2023.
  • Launching RezvoglarTM (insulin glargine-aglr) injection, a basal insulin that is biosimilar to, and interchangeable with, Lantus® (insulin glargine) injection, for $92 per five pack of KwikPens®, a 78% discount to Lantus, effective April 1, 2023.

You May Also Like
TownLift Is Brought To You In Part By These Presenting Partners.

Add Your Organization